MedTrace Logo

Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers

NCT03941340 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-01-06

No results posted yet for this study

Summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose\[14C\] AST2818 in Chinese Healthy Male Volunteers

Conditions

  • Healthy Male Volunteers

Interventions

DRUG

[14]-AST2818

Volunteer will receive a single oral dose of 80 mg /100 u Ci \[14C\]-AST2818 as a solution on Day 1

Sponsors & Collaborators

  • Allist Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • LiYan Miu · First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-08
Primary Completion
2019-09-06
Completion
2019-09-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03941340 on ClinicalTrials.gov